Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

CoCA · Comorbid Conditions of Attention deficit / hyperactivity disorder

H2020Status: CLOSED1 January 201630 June 2021EU funding €5,999,021Call H2020-PHC-2014-2015

Understanding mechanisms underlying comorbid disorders poses a challenge for developing precision medicine tools. Psychiatric disorders are highly comorbid, and are among the last areas of medicine, where classification is driven by phenomenology rather than pathophysiology. We will study comorbidity between the most frequent psychiatric conditions, ADHD, mood/anxiety, and substance use disorders, and a highly prevalent somatic disease, obesity. ADHD, a childhood-onset disorder, forms the entry into a lifelong negative trajectory characterized by these comorbidities. Common mechanisms underlying this course are unknown, despite their relevance for early detection, prevention, and treatment. Our interdisciplinary team of experts will integrate epidemiologic/genetic approaches with experimental designs to address those issues. We will determine disease burden of comorbidity, calculate its socioeconomic impact, and reveal risk factors. We will study biological pathways of comorbidity and derive biomarkers, prioritizing two candidate mechanisms (circadian rhythm and dopaminergic neurotransmission), but also leveraging large existing data sets to identify new ones. A pilot clinical trial to study non-pharmacologic, dopamine-based and chronobiological treatments will be performed, employing innovative mHealth to monitor and support patients’ daily life. Integration of findings will lead to prediction algorithms enhancing early diagnosis and prevention of comorbidity. Finally, we will screen to repurpose existing pharmacological compounds. Integrating complementary approaches based on large-scale, existing data and innovative data collection, we maximize value for money in this project, leading to insight into the mechanisms underlying this comorbidity triad with its huge burden for healthcare, economy, and society. This will facilitate early detection and non-invasive, scalable, and low-cost treatment, creating opportunities for substantial and immediate societal impact.

Consortium · 18 organisations

coordinator

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN

DE · €996,898

participant

AARHUS UNIVERSITET

DK · €261,805

participant

TARTU ULIKOOL

EE · €147,000

participant

THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

US · €312,000

participant

STICHTING RADBOUD UNIVERSITEIT

NL

participant

UNIVERSIDAD DE GRANADA

ES · €105,000

participant

ACADEMISCH ZIEKENHUIS GRONINGEN

NL · €262,000

participant

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM

NL · €585,000

participant

KARLSRUHER INSTITUT FUER TECHNOLOGIE

DE · €466,913

participant

UNIVERSITAT DE BARCELONA

ES · €252,391

participant

UNIVERSITATSMEDIZIN ROSTOCK

DE · €240,000

participant

UNIVERSITATSKLINIKUM HEIDELBERG

DE · €339,658

participant

KAROLINSKA INSTITUTET

SE · €202,000

participant

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

ES · €326,996

participant

CONCENTRIS RESEARCH MANAGEMENT GMBH

DE · €360,000

participant

UNIVERSITETET I BERGEN

NO · €402,360

participant

HGC HEALTHCARE CONSULTANTS GMBH

DE · €150,000

participant

KING'S COLLEGE LONDON

UK · €589,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.